Opthalmologists can tell a great deal about someone's overall health just by looking into their eyes. From retinal detachments, cataracts and glaucomas to diseases such as cancer and diabetes, many serious conditions can be detected early on via eye exams. The major benefit is that these are cheap and non-invasive compared to many procedures.
Optos was set up in 1992 after founder Douglas Anderson's five-year-old son became blind in one eye. The firm is now the global leader in retinal diagnostics: more than 4,500 of its scanning machines are installed worldwide the majority in America. These instruments take wide-angle, high-resolution digital images (optomaps') of 82% of the retina. No other device can do this in a single picture. The devices are backed by a raft of clinical data, giving Optos a major competitive edge in this $2bn-$3bn market.
Chief executive Roy Davis's goal is to deliver sustainable organic growth of 20% a year, with operating profit margins of 20%, by expanding geographically and across product categories.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
In the first half, sales from outside North America more than doubled to $19m. Progress was also made towards securing higher recurring revenues by moving customers towards a finance lease model (in other words, renting rather than buying machines). Strong renewal rates saw receipts from future rental contracts reach $144m, even as outright sales more than doubled to $22.7m.
Davis is also excited about the new Daytona machine. This is lighter than previous models, more reliable and cheaper to make, which should open doors in both emerging markets and smaller eye clinics, which are more price-sensitive. It could be a game-changer for the firm: the device has already generated $17m in advance orders, which are scheduled for shipment by 30 September.
Optos (LSE: OPTS), rated a BUY by Jefferies
Manufacturing capacity is scaling up too, with the full product launch slated for October. The City expects 2012 turnover and adjusted earnings per share (EPS) of $185m and 21 cents respectively, rising to $190m and 28 cents a year later. I value the group on a sales multiple of two, which, after deducting net debt of $48m, generates a value of around 250p a share.
The business is largely dependent on one science (the patented optomap), which does expose Optos to the risk that rivals might develop better products. There's also the problem of ensuring it can deliver on demand for the Daytonas. Currency fluctuations are also a risk. But overall Optos looks well placed to benefit from the opportunities in this niche area. Jefferies has a target price of 270p. The next update is due in October.
Rating: BUY at 180p (market cap £130m)
Paul also writes the Precision Guided Investments newsletter. See moneyweek.com/PGI, or call 020-7633 3634.
-
The top stocks in the FTSE 100After a year of strong returns for the UK’s flagship index, which FTSE 100 stocks have posted the best performance in 2024?
-
A junior ISA could turn your child’s pocket money into thousands of poundsPersuading your child to put their pocket money in a junior ISA might be difficult, but the pennies could quickly grow into pounds – and teach them a valuable lesson about money
-
Somero: trading this overlooked bargainFeatures Mechanical-screed maker Somero dominates its niche and is attractively valued. Matthew Partridge picks the best way to trade it.
-
How to find big profits in small companiesCover Story The small- and micro-cap sectors are risky and volatile. But with careful research and patience, investors could make huge gains. Matthew Partridge explains how to find the market’s top tiddlers.
-
The hidden gems on Aim, London's junior marketFeatures Aim, London’s junior market, is risky – but you can find solid stocks at low prices. Scott Longley reports.
-
Is Aim finally coming of age?Features The Aim market of mostly smaller companies has traditionally been seen as a bit of a backwater. Is it time to change that view? Matthew Partridge talks to Paul Latham and Richard Power of fund management company Octopus.
-
Three Aim-listed firms that will thrive in a post-Brexit worldOpinion Matt Tonge and Victoria Stevens of the Liontrust UK Smaller Companies Fund pick three Aim-listed firms that will survive Brexit turmoil.
-
Fetch! The Chinese small-cap stocks to buy in the Year of the Dog
Opinion Each week, a professional investor tells us where she’d put her money. This week: Tiffany Hsiao of Matthews Asia selects three Chinese small-cap stocks with exciting potential.
-
Small and mid-cap stocks with big potential
Opinion Professional investor Guy Anderson of the Mercantile Investment Trust selects three small and medium-sized firms with promising prospects that the market has missed.
-
Get cheap, reliable growth from smaller companiesFeatures One of the most reliable long-term investment trends is the long-term outperformance of smaller companies over blue chips. Max King picks some of the best ways to buy into this growth.
